Evidence map›Paper›PMID 40103889›Full record

ReviewPakistan journal of medical sciences2025

Association between fatty liver disease and risk of microvascular complications in Type-2 diabetes mellitus: A systematic review and meta-analysis.

Jiawei Shao, Mi Zhou, Xiaoqing Xie, Shaobo Lan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jiawei ShaoJiawei Shao, Department of Hepatology, Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang Province 421002, P.R. China.
Mi ZhouMi Zhou, Department of Dermatology, Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang Province 421002, P.R. China.
Xiaoqing XieXiaoqing Xie, Department of Hepatology, Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang Province 421002, P.R. China.
Shaobo LanShaobo Lan, Department of Hepatology, Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang Province 421002, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To summarize the existing evidence on the association between non-alcoholic fatty liver disease (NAFLD) and the probability of microvascular complications in Type-2 diabetes mellitus (T2DM). Methods: PubMed, EMBASE and Scopus databases search (from inception until October 31, 2023) was done for reports with cross-sectional, cohort or case-control design that included adult participants with T2DM and a documented NAFLD status. The selected studies were required to report on at least one microvascular outcome. Studies reporting adjusted associations were included. Random-effects models were used for all analysis. The pooled effect sizes for the associations were reported as odds ratio (OR) with 95% confidence intervals (CI). Results: Sixteen studies were analysed. T2DM patients with associated NAFLD had similar risk of neuropathy (OR 1.08, 95% CI: 0.97, 1.21), compared to those without NALFD. NAFLD was associated with slightly lower risk of retinopathy (OR 0.86, 95% CI: 0.75, 0.98; N=10, I Conclusion: Diagnosis of NAFLD in patients with T2DM appears to increase the incidence of nephropathy and decrease the risk of retinopathy. Future studies are needed to confirm these observations.

Indexed as

Meta-analysisMicrovascular complicationsNAFLDNephropathyNeuropathyNon-alcoholic fatty liver diseaseRetinopathyType-2 diabetes mellitus

Identifiers

PMID40103889
PMCPMC11911733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.